The Prokineticin System in Inflammatory Bowel Diseases: A Clinical and Preclinical Overview
Abstract
:1. Introduction
2. Methodology
- No filter time.
- Database: PubMed, Cochrane Library, and Embase.
- Language: only full-text in English.
- Keywords: terms used were “prokineticin system” OR “prokineticin 1” OR “prokineticin 2” OR “prokineticin receptors” combined with “inflammatory bowel disease” OR “Crohn’s Disease” OR “ulcerative colitis” through the Boolean operator AND.
- Key terms were searched in the title, abstract, and keywords of the papers. The search was open to all parameters in order to avoid information loss. MeSH terms were not used.
- The papers’ selection was based on a critical reading.
3. The Prokineticin System: A General Overview
4. The Role of the PKS in Inflammatory Bowel Disease
4.1. Evidence of the PKS in Gastrointestinal Motility, Contraction, and Secretion
4.2. Evidence of the PKS in Angiogenesis and Inflammation
4.3. Evidence of the PKS in Gastrointestinal Tumorigenesis in IBDs
4.4. Evidence of the PKS in Pain: Focus on IBD Model
4.5. Evidence of the PKS in IBD Patients
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Zhang, Y.-Z.; Li, Y.-Y. Inflammatory bowel disease: Pathogenesis. World J. Gastroenterol. 2014, 20, 91–99. [Google Scholar] [CrossRef]
- Kaplan, G.G. The global burden of IBD: From 2015 to 2025. Nat. Rev. Gastroenterol. Hepatol. 2015, 12, 720–727. [Google Scholar] [CrossRef] [PubMed]
- Jairath, V.; Feagan, B.G. Global burden of inflammatory bowel disease. Lancet Gastroenterol. Hepatol. 2020, 5, 2–3. [Google Scholar] [CrossRef] [PubMed]
- Lemmens, B.; De Hertogh, G.; Sagaert, X. Inflammatory Bowel Diseases. Pathobiol. Hum. Dis. 2014, 2014, 1297–1304. [Google Scholar] [CrossRef]
- Liverani, E.; Scaioli, E.; Digby, R.J.; Bellanova, M.; Belluzzi, A. How to predict clinical relapse in inflammatory bowel disease patients. World J. Gastroenterol. 2016, 22, 1017–1033. [Google Scholar] [CrossRef]
- Davis, J.; Kellerman, R. Gastrointestinal Conditions: Inflammatory Bowel Disease. FP Essent. 2022, 516, 23–30. [Google Scholar]
- Bielefeldt, K.; Davis, B.; Binion, D.G. Pain and inflammatory bowel disease. Inflamm. Bowel Dis. 2009, 15, 778–788. [Google Scholar] [CrossRef]
- Pinho-Ribeiro, F.A.; Verri, W.A., Jr.; Chiu, I.M. Nociceptor Sensory Neuron–Immune Interactions in Pain and Inflammation. Trends Immunol. 2017, 38, 5–19. [Google Scholar] [CrossRef]
- Aziz, M.N.M.; Kumar, J.; Muhammad Nawawi, K.N.; Raja Ali, R.A.; Mokhtar, N.M. Irritable Bowel Syndrome, Depression, and Neurodegeneration: A Bidirectional Communication from Gut to Brain. Nutrients 2021, 13, 3061. [Google Scholar] [CrossRef]
- Bisgaard, T.H.; Allin, K.H.; Keefer, L.; Ananthakrishnan, A.N.; Jess, T. Depression and anxiety in inflammatory bowel disease: Epidemiology, mechanisms and treatment. Nat. Rev. Gastroenterol. Hepatol. 2022, 19, 717–726. [Google Scholar] [CrossRef]
- Geremia, A.; Biancheri, P.; Allan, P.; Corazza, G.R.; Di Sabatino, A. Innate and adaptive immunity in inflammatory bowel disease. Autoimmun. Rev. 2014, 13, 3–10. [Google Scholar] [CrossRef] [PubMed]
- Leppkes, M.; Neurath, M.F. Cytokines in inflammatory bowel diseases—Update 2020. Pharmacol. Res. 2020, 158, 104835. [Google Scholar] [CrossRef] [PubMed]
- Rizzo, G.; Rubbino, F.; Elangovan, S.; Sammarco, G.; Lovisa, S.; Restelli, S.; Pineda Chavez, S.E.; Massimino, L.; Lamparelli, L.; Paulis, M.; et al. Dysfunctional Extracellular Matrix Remodeling Supports Perianal Fistulizing Crohn’s Disease by a Mechanoregulated Activation of the Epithelial-to-Mesenchymal Transition. Cell. Mol. Gastroenterol. Hepatol. 2023, 15, 741–764. [Google Scholar] [CrossRef] [PubMed]
- Ananthakrishnan, A.N.; Bernstein, C.N.; Iliopoulos, D.; Macpherson, A.; Neurath, M.F.; Ali, R.A.R.; Vavricka, S.R.; Fiocchi, C. Environmental triggers in IBD: A review of progress and evidence. Nat. Rev. Gastroenterol. Hepatol. 2018, 15, 39–49. [Google Scholar] [CrossRef]
- Mann, E.A.; Saeed, S.A. Gastrointestinal infection as a trigger for inflammatory bowel disease. Curr. Opin. Gastroenterol. 2012, 28, 24–29. [Google Scholar] [CrossRef]
- Schroeder, B.O.; Birchenough, G.M.H.; Stahlman, M.; Arike, L.; Johansson, M.E.V.; Hansson, G.C.; Backhed, F. Bifidobacteria or Fiber Protects against Diet-Induced Microbiota-Mediated Colonic Mucus Deterioration. Cell Host Microbe. 2018, 23, 27–40.e7. [Google Scholar] [CrossRef]
- Neurath, M.F.; Leppkes, M. Resolution of ulcerative colitis. Semin. Immunopathol. 2019, 41, 747–756. [Google Scholar] [CrossRef]
- MacDermott, R.P.; Stenson, W.F. Alterations of the immune system in ulcerative colitis and Crohn’s disease. Adv. Immunol. 1988, 42, 285–328. [Google Scholar] [CrossRef]
- Mollay, C.; Wechselberger, C.; Mignogna, G.; Negri, L.; Melchiorri, P.; Barra, D.; Kreil, G. Bv8, a small protein from frog skin and its homologue from snake venom induce hyperalgesia in rats. Eur. J. Pharmacol. 1999, 374, 189–196. [Google Scholar] [CrossRef]
- Schweitz, H.; Pacaud, P.; Diochot, S.; Moinier, D.; Lazdunski, M. MIT1, a black mamba toxin with a new and highly potent activity on intestinal contraction. FEBS Lett. 1999, 461, 183–188. [Google Scholar] [CrossRef]
- Joubert, F.J.; Strydom, D.J. Snake venom. The amino acid sequence of protein A from Dendroaspis polylepis polylepis (black mamba) venom. Hoppe Seylers Z Physiol. Chem. 1980, 361, 1787–1794. [Google Scholar] [CrossRef] [PubMed]
- Li, M.; Bullock, C.M.; Knauer, D.J.; Ehlert, F.J.; Zhou, Q.Y. Identification of two prokineticin cDNAs: Recombinant proteins potently contract gastrointestinal smooth muscle. Mol. Pharmacol. 2001, 59, 692–698. [Google Scholar] [CrossRef] [PubMed]
- Monnier, J.; Samson, M. Cytokine properties of prokineticins. FEBS J. 2008, 275, 4014–4021. [Google Scholar] [CrossRef] [PubMed]
- Negri, L.; Lattanzi, R.; Giannini, E.; Canestrelli, M.; Nicotra, A.; Melchiorri, P. Bv8/Prokineticins and their Receptors: A New Pronociceptive System. Int. Rev. Neurobiol. 2009, 85, 145–157. [Google Scholar] [CrossRef]
- Lattanzi, R.; Miele, R. Prokineticin-Receptor Network: Mechanisms of Regulation. Life 2022, 12, 172. [Google Scholar] [CrossRef]
- Kaser, A.; Winklmayr, M.; Lepperdinger, G.; Kreil, G. The AVIT protein family: Secreted cysteine-rich vertebrate proteins with diverse functions. EMBO Rep. 2003, 4, 469–473. [Google Scholar] [CrossRef]
- Lin, D.C.-H.; Bullock, C.M.; Ehlert, F.J.; Chen, J.-L.; Tian, H.; Zhou, Q.-Y. Identification and molecular characterization of two closely related G protein-coupled receptors activated by prokineticins/endocrine gland vascular endothelial growth factor. J. Biol. Chem. 2002, 277, 19276–19280. [Google Scholar] [CrossRef]
- Negri, L.; Ferrara, N. The Prokineticins: Neuromodulators and Mediators of Inflammation and Myeloid Cell-Dependent Angiogenesis. Physiol. Rev. 2018, 98, 1055–1082. [Google Scholar] [CrossRef]
- Franchi, S.; Sacerdote, P.; Panerai, A. The prokineticin system: An interface between neural inflammation and pain. Neurol. Sci. 2017, 38, 27–30. [Google Scholar] [CrossRef]
- Amodeo, G.; Maftei, D.; Lattanzi, R.; Verduci, B.; Comi, L.; Galimberti, G.; Sacerdote, P.; Franchi, S. Controlling the activation of the prokineticin system as therapeutic approach to relief neuropathic pain and reduce neuroinflammation. Pharmadvance 2022, 4, 104–120. [Google Scholar] [CrossRef]
- Cheng, M.Y.; Bullock, C.M.; Li, C.; Lee, A.G.; Bermak, J.C.; Belluzzi, J.; Weaver, D.R.; Leslie, F.M.; Zhou, Q.-Y. Prokineticin 2 transmits the behavioural circadian rhythm of the suprachiasmatic nucleus. Nature 2002, 417, 405–410. [Google Scholar] [CrossRef] [PubMed]
- Nebigil, C.G. Prokineticin receptors in cardiovascular function: Foe or friend? Trends Cardiovasc. Med. 2009, 19, 55–60. [Google Scholar] [CrossRef] [PubMed]
- LeCouter, J.; Zlot, C.; Tejada, M.; Peale, F.; Ferrara, N. Bv8 and endocrine gland-derived vascular endothelial growth factor stimulate hematopoiesis and hematopoietic cell mobilization. Proc. Natl. Acad. Sci. USA 2004, 101, 16813–16818. [Google Scholar] [CrossRef] [PubMed]
- Lattanzi, R.; Miele, R. Non-Peptide Agonists and Antagonists of the Prokineticin Receptors. Curr. Issues Mol. Biol. 2022, 44, 6323–6332. [Google Scholar] [CrossRef] [PubMed]
- Lattanzi, R.; Severini, C.; Maftei, D.; Saso, L.; Badiani, A. The Role of Prokineticin 2 in Oxidative Stress and in Neuropathological Processes. Front. Pharmacol. 2021, 12, 640441. [Google Scholar] [CrossRef] [PubMed]
- Lattanzi, R.; Severini, C.; Miele, R. Prokineticin 2 in cancer-related inflammation. Cancer Lett. 2022, 546, 215838. [Google Scholar] [CrossRef]
- Maftei, D.; Schirinzi, T.; Mercuri, N.B.; Lattanzi, R.; Severini, C. Potential Clinical Role of Prokineticin 2 (PK2) in Neurodegenerative Diseases. Curr. Neuropharmacol. 2022, 20, 2019–2023. [Google Scholar] [CrossRef]
- Zhao, Y.; Wu, J.; Wang, X.; Jia, H.; Chen, D.-N.; Li, J.-D. Prokineticins and their G protein-coupled receptors in health and disease. Prog. Mol. Biol. Transl. Sci. 2019, 161, 149–179. [Google Scholar] [CrossRef]
- Amodeo, G.; Galimberti, G.; Sacerdote, P.; Franchi, S. Characterization of prokineticin system in Crohn’s disease pathophysiology and pain, and its modulation by alcohol abuse: A preclinical study. Biochim. Biophys. Acta Mol. Basis Dis. 2023, 17, 166791. [Google Scholar] [CrossRef]
- Abdalla, S.M.; Kalra, G.; Moshiree, B. Motility Evaluation in the Patient with Inflammatory Bowel Disease. Gastrointest. Endosc. Clin. N. Am. 2016, 26, 719–738. [Google Scholar] [CrossRef]
- Barros, L.L.; Farias, A.Q.; Rezaie, A. Gastrointestinal motility and absorptive disorders in patients with inflammatory bowel diseases: Prevalence, diagnosis and treatment. World J. Gastroenterol. 2019, 25, 4414–4426. [Google Scholar] [CrossRef]
- Bryant, R.V.; van Langenberg, D.R.; Holtmann, G.J.; Andrews, J.M. Functional gastrointestinal disorders in inflammatory bowel disease: Impact on quality of life and psychological status. J. Gastroenterol. Hepatol. 2011, 26, 916–923. [Google Scholar] [CrossRef] [PubMed]
- Spiller, R.; Major, G. IBS and IBD—Separate entities or on a spectrum? Nat. Rev. Gastroenterol. Hepatol. 2016, 13, 613–621. [Google Scholar] [CrossRef] [PubMed]
- Bassotti, G.; Antonelli, E.; Villanacci, V.; Salemme, M.; Coppola, M.; Annese, V. Gastrointestinal motility disorders in inflammatory bowel diseases. World J. Gastroenterol. 2014, 20, 37–44. [Google Scholar] [CrossRef] [PubMed]
- Bassotti, G.; Antonelli, E.; Villanacci, V.; Nascimbeni, R.; Dore, M.P.; Pes, G.M.; Maconi, G. Abnormal gut motility in inflammatory bowel disease: An update. Tech. Coloproctology 2020, 24, 275–282. [Google Scholar] [CrossRef] [PubMed]
- Villanacci, V.; Bassotti, G.; Nascimbeni, R.; Antonelli, E.; Cadei, M.; Fisogni, S.; Salerni, B.; Geboes, K. Enteric nervous system abnormalities in inflammatory bowel diseases. Neurogastroenterol. Motil. 2008, 20, 1009–1016. [Google Scholar] [CrossRef]
- Bassotti, G.; Villanacci, V.; Nascimbeni, R.; Cadei, M.; Fisogni, S.; Antonelli, E.; Corazzi, N.; Salerni, B. Enteric neuroglial apoptosis in inflammatory bowel diseases. J. Crohn’s Colitis 2009, 3, 264–270. [Google Scholar] [CrossRef]
- Lewis, K.E.; Garcia, R.M.; Kim, K.; West, R.R.; Thompson, P.J.; Gilbertson, D.G. Prokinetiein-2, a Potential Novel Protein Therapeutic, Increases Post-Operative Gastric and Intestinal Motility in Rats. AGA Abstr. 2004, 126, A641. [Google Scholar]
- Bassil, A.K.; Dass, N.B.; Murray, C.D.; Muir, A.; Sanger, G.J. Prokineticin-2, motilin, ghrelin and metoclopramide: Prokinetic utility in mouse stomach and colon. Eur. J. Pharmacol. 2005, 524, 138–144. [Google Scholar] [CrossRef]
- Watson, R.P.; Lilley, E.; Panesar, M.; Bhalay, G.; Langridge, S.; Tian, S.S.; McClenaghan, C.; Ropenga, A.; Zeng, F.; Nash, M.S. Increased prokineticin 2 expression in gut inflammation: Role in visceral pain and intestinal ion transport. Neurogastroenterol. Motil. 2012, 24, 65-e12. [Google Scholar] [CrossRef]
- Wade, P.R.; Mabus, J.R.; Palmer, J.M.; Prouty, S.M.; Saunders, P.R.; Mckenney, S.L.; Chevalier, K.M.; Hornby, P.J. Prokineticin-1 Receptor Mediates Intestinal Secretory and Contractile Activity. Gastroenterology 2007, 132 (Suppl. S2), A223. [Google Scholar] [CrossRef]
- Zhou, C.; Zhao, J.; Wu, L.; Huang, R.; Shi, Y.; Wang, X.; Liao, W.; Hong, J.; Liu, S.; Wu, H. Mild moxibustion decreases the expression of prokineticin 2 and prokineticin receptor 2 in the colon and spinal cord of rats with irritable bowel syndrome. Evid.-Based Complement. Altern. Med. 2014, 2014, 807308. [Google Scholar] [CrossRef]
- Hoogerwerf, W.A. Prokineticin 1 inhibits spontaneous giant contractions in the murine proximal colon through nitric oxide release. Neurogastroenterol. Motil. 2006, 18, 455–463. [Google Scholar] [CrossRef] [PubMed]
- Ngan, E.S.; Lee, K.Y.; Sit, F.Y.; Poon, H.C.; Chan, J.K.; Sham, M.H.; Lui, V.C.; Tam, P.K. Prokineticin-1 modulates proliferation and differentiation of enteric neural crest cells. Biochim. Biophys. Acta-Mol. Cell Res. 2007, 1773, 536–545. [Google Scholar] [CrossRef] [PubMed]
- Ngan, E.S.; Shum, C.K.; Poon, H.-C.; Sham, M.-H.; Garcia-Barcelo, M.-M.; Lui, V.C.; Tam, P.K. Prokineticin-1 (Prok-1) works coordinately with glial cell line-derived neurotrophic factor (GDNF) to mediate proliferation and differentiation of enteric neural crest cells. Biochim. Biophys. Acta-Mol. Cell Res. 2008, 1783, 467–478. [Google Scholar] [CrossRef]
- Ngan, E.S.; Tam, P.K. Prokineticin-signaling pathway. Int. J. Biochem. Cell Biol. 2008, 40, 1679–1684. [Google Scholar] [CrossRef]
- Wade, P.R.; Palmer, J.M.; Mabus, J.; Saunders, P.R.; Prouty, S.; Chevalier, K.; Gareau, M.G.; McKenney, S.; Hornby, P.J. Prokineticin-1 evokes secretory and contractile activity in rat small intestine. Neurogastroenterol. Motil. 2010, 22, e152–e161. [Google Scholar] [CrossRef] [PubMed]
- Neurath, M.F. Cytokines in inflammatory bowel disease. Nat. Rev. Immunol. 2014, 14, 329–342. [Google Scholar] [CrossRef]
- Neuman, M.G. Immune dysfunction in inflammatory bowel disease. Transl. Res. 2007, 149, 173–186. [Google Scholar] [CrossRef]
- Strober, W.; Fuss, I.J.; Blumberg, R.S. The immunology of mucosal models of inflammation. Annu. Rev. Immunol. 2002, 20, 495–549. [Google Scholar] [CrossRef]
- Alkim, C.; Alkim, H.; Koksal, A.R.; Boga, S.; Sen, I. Angiogenesis in Inflammatory Bowel Disease. Int. J. Inflamm. 2015, 2015, 970890. [Google Scholar] [CrossRef] [PubMed]
- LeCouter, J.; Kowalski, J.; Foster, J.; Hass, P.; Zhang, Z.; Dillard-Telm, L.; Frantz, G.; Rangell, L.; DeGuzman, L.; Keller, G.A.; et al. Identification of an angiogenic mitogen selective for endocrine gland endothelium. Nature 2001, 412, 877–884. [Google Scholar] [CrossRef] [PubMed]
- Lin, R.; LeCouter, J.; Kowalski, J.; Ferrara, N. Characterization of endocrine gland-derived vascular endothelial growth factor signaling in adrenal cortex capillary endothelial cells. J. Biol. Chem. 2002, 277, 8724–8729. [Google Scholar] [CrossRef] [PubMed]
- Dorsch, M.; Qiu, Y.; Soler, D.; Frank, N.; Duong, T.; Goodearl, A.; O’Neil, S.; Lora, J.; Fraser, C.C. PK1/EG-VEGF induces monocyte differentiation and activation. J. Leukoc. Biol. 2005, 78, 426–434. [Google Scholar] [CrossRef]
- Nakazawa, T.; Goi, T.; Hirono, Y.; Yamaguchi, A. Prokineticin 1 protein expression is a useful new prognostic factor for human sporadic colorectal cancer. Ann. Surg. Oncol. 2015, 22, 1496–1503. [Google Scholar] [CrossRef]
- Martucci, C.; Franchi, S.; Giannini, E.; Tian, H.; Melchiorri, P.; Negri, L.; Sacerdote, P. Bv8, the amphibian homologue of the mammalian prokineticins, induces a proinflammatory phenotype of mouse macrophages. Br. J. Pharmacol. 2006, 147, 225–234. [Google Scholar] [CrossRef]
- Franchi, S.; Giannini, E.; Lattuada, D.; Lattanzi, R.; Tian, H.; Melchiorri, P.; Negri, L.; Panerai, A.E.; Sacerdote, P. The prokineticin receptor agonist Bv8 decreases IL-10 and IL-4 production in mice splenocytes by activating prokineticin receptor-1. BMC Immunol. 2008, 9, 60. [Google Scholar] [CrossRef]
- Nagao-Kitamoto, H.; Kitamoto, S.; Kamada, N. Inflammatory bowel disease and carcinogenesis. Cancer Metastasis Rev. 2022, 41, 301–316. [Google Scholar] [CrossRef]
- Eaden, J.A.; Abrams, K.R.; Mayberry, J.F. The risk of colorectal cancer in ulcerative colitis: A meta-analysis. Gut 2001, 48, 526–535. [Google Scholar] [CrossRef]
- Bajpai, M.; Seril, D.N.; Van Gurp, J.; Geng, X.; Alvarez, J.; Minacapelli, C.D.; Gorin, S.; Das, K.K.; Poplin, E.; Cheng, J.; et al. Effect of Long-Term Mesalamine Therapy on Cancer-Associated Gene Expression in Colonic Mucosa of Patients with Ulcerative Colitis. Dig. Dis. Sci. 2019, 64, 740–750. [Google Scholar] [CrossRef]
- Lucafò, M.; Curci, D.; Franzin, M.; Decorti, G.; Stocco, G. Inflammatory Bowel Disease and Risk of Colorectal Cancer: An Overview From Pathophysiology to Pharmacological Prevention. Front. Pharmacol. 2021, 12, 772101. [Google Scholar] [CrossRef] [PubMed]
- Ullman, T.A.; Itzkowitz, S.H. Intestinal inflammation and cancer. Gastroenterology 2011, 140, 1807–1816. [Google Scholar] [CrossRef]
- Baker, K.T.; Salk, J.J.; Brentnall, T.A.; Risques, R.A. Precancer in ulcerative colitis: The role of the field effect and its clinical implications. Carcinogenesis 2018, 39, 11–20. [Google Scholar] [CrossRef] [PubMed]
- Long, A.G.; Lundsmith, E.T.; Hamilton, K.E. Inflammation and Colorectal Cancer. Curr. Color. Cancer Rep. 2017, 13, 341–351. [Google Scholar] [CrossRef]
- Pasquali, D.; Rossi, V.; Staibano, S.; De Rosa, G.; Chieffi, P.; Prezioso, D.; Mirone, V.; Mascolo, M.; Tramontano, D.; Bellastella, A.; et al. The endocrine-gland-derived vascular endothelial growth factor (EG-VEGF)/prokineticin 1 and 2 and receptor expression in human prostate: Up-regulation of EG-VEGF/prokineticin 1 with malignancy. Endocrinology 2006, 147, 4245–4251. [Google Scholar] [CrossRef] [PubMed]
- Bălu, S.; Pirtea, L.; Gaje, P.; Cîmpean, A.M.; Raica, M. The immunohistochemical expression of endocrine gland-derived-VEGF (EG-VEGF) as a prognostic marker in ovarian cancer. Rom. J. Morphol. Embryol. 2012, 53, 479–483. [Google Scholar] [PubMed]
- Ren, L.; Guo, X.; Shao, X.; Li, H.; Yao, H. Endocrine gland derived vascular endothelial growth factor modulates proliferation, apoptosis and migration in pancreatic cancer cells. Mol. Med. Rep. 2015, 11, 4279–4284. [Google Scholar] [CrossRef]
- Heck, D.; Wortmann, S.; Kraus, L.; Ronchi, C.L.; Sinnott, R.O.; Fassnacht, M.; Sbiera, S. Role of Endocrine Gland-Derived Vascular Endothelial Growth Factor (EG-VEGF) and Its Receptors in Adrenocortical Tumors. Horm. Cancer 2015, 6, 225–236. [Google Scholar] [CrossRef]
- Nagano, H.; Goi, T.; Koneri, K.; Hirono, Y.; Katayama, K.; Yamaguchi, A. Endocrine gland-derived vascular endothelial growth factor (EG-VEGF) expression in colorectal cancer. J. Surg. Oncol. 2007, 96, 605–610. [Google Scholar] [CrossRef]
- Tagai, N.; Goi, T.; Shimada, M.; Kurebayashi, H. Plasma Prokineticin 1, a prognostic biomarker in colorectal cancer patients with curative resection: A retrospective cohort study. World J. Surg. Oncol. 2021, 19, 302. [Google Scholar] [CrossRef]
- Kurebayashi, H.; Goi, T.; Shimada, M.; Tagai, N.; Naruse, T.; Nakazawa, T.; Kimura, Y.; Hirono, Y.; Yamaguchi, A. Prokineticin 2 (PROK2) is an important factor for angiogenesis in colorectal cancer. Oncotarget 2015, 6, 26242–26251. [Google Scholar] [CrossRef] [PubMed]
- Yoshida, Y.; Goi, T.; Kurebayashi, H.; Morikawa, M.; Hirono, Y.; Katayama, K. Prokineticin 2 expression as a novel prognostic biomarker for human colorectal cancer. Oncotarget 2018, 9, 30079–30091. [Google Scholar] [CrossRef] [PubMed]
- Negri, L.; Lattanzi, R.; Giannini, E.; Metere, A.; Colucci, M.; Barra, D.; Kreil, G.; Melchiorri, P. Nociceptive sensitization by the secretory protein Bv8. Br. J. Pharmacol. 2002, 137, 1147–1154. [Google Scholar] [CrossRef] [PubMed]
- Vellani, V.; Colucci, M.; Lattanzi, R.; Giannini, E.; Negri, L.; Melchiorri, P.; McNaughton, P.A. Sensitization of transient receptor potential vanilloid 1 by the prokineticin receptor agonist Bv8. J. Neurosci. 2006, 26, 5109–5116. [Google Scholar] [CrossRef] [PubMed]
- De Novellis, V.; Negri, L.; Lattanzi, R.; Rossi, F.; Palazzo, E.; Marabese, I.; Giannini, E.; Vita, D.; Melchiorri, P.; Maione, S. The prokineticin receptor agonist Bv8 increases GABA release in the periaqueductal grey and modifies RVM cell activities and thermoceptive reflexes in the rat. Eur. J. Neurosci. 2007, 26, 3068–3078. [Google Scholar] [CrossRef] [PubMed]
- De Felice, M.; Melchiorri, P.; Ossipov, M.H.; Vanderah, T.W.; Porreca, F.; Negri, L. Mechanisms of Bv8-induced biphasic hyperalgesia: Increased excitatory transmitter release and expression. Neurosci. Lett. 2012, 521, 40–45. [Google Scholar] [CrossRef] [PubMed]
- Hu, W.-P.; Zhang, C.; Li, J.-D.; Luo, Z.D.; Amadesi, S.; Bunnett, N.; Zhou, Q.-Y. Impaired pain sensation in mice lacking prokineticin 2. Mol. Pain 2006, 2, 35. [Google Scholar] [CrossRef]
- Negri, L.; Lattanzi, R.; Giannini, E.; Colucci, M.; Margheriti, F.; Melchiorri, P.; Vellani, V.; Tian, H.; De Felice, M.; Porreca, F. Impaired nociception and inflammatory pain sensation in mice lacking the prokineticin receptor PKR1: Focus on interaction between PKR1 and the capsaicin receptor TRPV1 in pain behavior. J. Neurosci. 2006, 26, 6716–6727. [Google Scholar] [CrossRef]
- Negri, L.; Lattanzi, R.; Giannini, E.; Melchiorri, P. Modulators of pain: Bv8 and prokineticins. Curr. Neuropharmacol. 2006, 4, 207–215. [Google Scholar] [CrossRef]
- Maftei, D.; Vellani, V.; Artico, M.; Giacomoni, C.; Severini, C.; Lattanzi, R. Abnormal Pain Sensation in Mice Lacking the Prokineticin Receptor PKR2: Interaction of PKR2 with Transient Receptor Potential TRPV1 and TRPA1. Neuroscience 2020, 427, 16–28. [Google Scholar] [CrossRef]
- Giannini, E.; Lattanzi, R.; Nicotra, A.; Campese, A.F.; Grazioli, P.; Screpanti, I.; Balboni, G.; Salvadori, S.; Sacerdote, P.; Negri, L. The chemokine Bv8/prokineticin 2 is up-regulated in inflammatory granulocytes and modulates inflammatory pain. Proc. Natl. Acad. Sci. USA 2009, 106, 14646–14651. [Google Scholar] [CrossRef] [PubMed]
- Galimberti, G.; Amodeo, G.; Magni, G.; Riboldi, B.; Balboni, G.; Onnis, V.; Ceruti, S.; Sacerdote, P.; Franchi, S. Prokineticin System Is a Pharmacological Target to Counteract Pain and Its Comorbid Mood Alterations in an Osteoarthritis Murine Model. Cells 2023, 12, 2255. [Google Scholar] [CrossRef] [PubMed]
- Maftei, D.; Marconi, V.; Florenzano, F.; Giancotti, L.A.; Castelli, M.; Moretti, S.; Borsani, E.; Rodella, L.F.; Balboni, G.; Luongo, L.; et al. Controlling the activation of the Bv8/prokineticin system reduces neuroinflammation and abolishes thermal and tactile hyperalgesia in neuropathic animals. Br. J. Pharmacol. 2014, 171, 4850–4865. [Google Scholar] [CrossRef] [PubMed]
- Guida, F.; Lattanzi, R.; Boccella, S.; Maftei, D.; Romano, R.; Marconi, V.; Balboni, G.; Salvadori, S.; Scafuro, M.A.; de Novellis, V.; et al. PC1, a non-peptide PKR1-preferring antagonist, reduces pain behavior and spinal neuronal sensitization in neuropathic mice. Pharmacol. Res. 2015, 91, 36–46. [Google Scholar] [CrossRef]
- Lattanzi, R.; Maftei, D.; Marconi, V.; Florenzano, F.; Franchi, S.; Borsani, E.; Rodella, L.F.; Balboni, G.; Salvadori, S.; Sacerdote, P.; et al. Prokineticin 2 upregulation in the peripheral nervous system has a major role in triggering and maintaining neuropathic pain in the chronic constriction injury model. Biomed. Res. Int. 2015, 2015, 301292. [Google Scholar] [CrossRef]
- Castelli, M.; Amodeo, G.; Negri, L.; Lattanzi, R.; Maftei, D.; Gotti, C.; Pistillo, F.; Onnis, V.; Congu, C.; Panerai, A.E.; et al. Antagonism of the Prokineticin System Prevents and Reverses Allodynia and Inflammation in a Mouse Model of Diabetes. PLoS ONE 2016, 11, e0146259. [Google Scholar] [CrossRef]
- Moschetti, G.; Amodeo, G.; Paladini, M.S.; Molteni, R.; Balboni, G.; Panerai, A.; Sacerdote, P.; Franchi, S. Prokineticin 2 promotes and sustains neuroinflammation in vincristine treated mice: Focus on pain and emotional like behavior. Brain Behav. Immun. 2019, 82, 422–431. [Google Scholar] [CrossRef]
- Moschetti, G.; Amodeo, G.; Maftei, D.; Lattanzi, R.; Procacci, P.; Sartori, P.; Balboni, G.; Onnis, V.; Conte, V.; Panerai, A.; et al. Targeting prokineticin system counteracts hypersensitivity, neuroinflammation, and tissue damage in a mouse model of bortezomib-induced peripheral neuropathy. J. Neuroinflammation 2019, 16, 89. [Google Scholar] [CrossRef]
- Moschetti, G.; Kalpachidou, T.; Amodeo, G.; Lattanzi, R.; Sacerdote, P.; Kress, M.; Franchi, S. Prokineticin Receptor Inhibition With PC1 Protects Mouse Primary Sensory Neurons From Neurotoxic Effects of Chemotherapeutic Drugs in vitro. Front. Immunol. 2020, 11, 2119. [Google Scholar] [CrossRef]
- Amodeo, G.; Verduci, B.; Sartori, P.; Procacci, P.; Conte, V.; Balboni, G.; Sacerdote, P.; Franchi, S. The Antagonism of the Prokineticin System Counteracts Bortezomib Induced Side Effects: Focus on Mood Alterations. Int. J. Mol. Sci. 2021, 22, 10256. [Google Scholar] [CrossRef]
- Rullo, L.; Franchi, S.; Amodeo, G.; Caputi, F.F.; Verduci, B.; Losapio, L.M.; Sacerdote, P.; Romualdi, P.; Candeletti, S. Interplay between Prokineticins and Histone Demethylase KDM6A in a Murine Model of Bortezomib-Induced Neuropathy. Int. J. Mol. Sci. 2021, 22, 11913. [Google Scholar] [CrossRef] [PubMed]
- Kimball, E.S.; Prouty, S.P.; Pavlick, K.P.; Wallace, N.H.; Schneider, C.R.; Hornby, P.J. Stimulation of neuronal receptors, neuropeptides and cytokines during experimental oil of mustard colitis. Neurogastroenterol. Motil. 2007, 19, 390–400. [Google Scholar] [CrossRef] [PubMed]
- Wu, L.Y.; Bao, C.H.; Ge, L.B.; Zhou, C.L.; Liu, H.R.; Qi, L.; Yi, T.; Wu, H.G.; Wang, X.M. Mild moxibustion at Tianshu (ST-25) decreases expression of prokineticin-1 and prokineticin receptor-1 in colon tissue of rats with chronic visceral hyperalgesia. Neural. Regen. Res. 2011, 6, 2600–2604. [Google Scholar] [CrossRef]
- Zinni, M.; Zuena, A.R.; Marconi, V.; Petrella, C.; Fusco, I.; Giuli, C.; Canu, N.; Severini, C.; Broccardo, M.; Theodorou, V.; et al. Maternal exposure to low levels of corticosterone during lactation protects adult rat progeny against TNBS-induced colitis: A study on GR-mediated anti-inflammatory effect and prokineticin system. PLoS ONE 2017, 12, e0173484. [Google Scholar] [CrossRef]
- Li, X.; Lee, E.J.; Gawel, D.R.; Lilja, S.; Schäfer, S.; Zhang, H.; Benson, M. Meta-Analysis of Expression Profiling Data Indicates Need for Combinatorial Biomarkers in Pediatric Ulcerative Colitis. J. Immunol. Res. 2020, 2020, 8279619. [Google Scholar] [CrossRef]
- Chen, Z.-A.; Ma, H.-H.; Wang, Y.; Tian, H.; Mi, J.-W.; Yao, D.-M.; Yang, C.-J. Integrated multiple microarray studies by robust rank aggregation to identify immune-associated biomarkers in Crohn’s disease based on three machine learning methods. Sci. Rep. 2023, 13, 2694. [Google Scholar] [CrossRef]
Ligand | Receptor | |||
---|---|---|---|---|
Organ/Tissue | PK1 | PK2 | PKR1 | PKR2 |
The brain | ||||
Olfactory bulb | N/A | + | + | + |
Other olfactory regions | N/A | N/A | N/A | + |
Olfactory ventricle | N/A | N/A | + | + |
Other ventricles | N/A | N/A | + | + |
Ependyma | N/A | N/A | + | + |
Cerebellum | + | + | N/A | N/A |
Medial preoptic area | N/A | + | N/A | N/A |
Lateral preoptic area | N/A | N/A | N/A | + |
Purkinje cells | N/A | + | N/A | N/A |
Paraventricular nucleus | N/A | N/A | N/A | + |
Nucleus arcuatus | N/A | + | + | + |
Nucleus accumbens | N/A | + | N/A | N/A |
Ventral pallidum | N/A | N/A | N/A | + |
Globus pallidus | N/A | N/A | N/A | + |
Calleja islands | N/A | + | N/A | N/A |
Suprachiasmatic nucleus | N/A | + | N/A | + |
Amygdala | N/A | + | N/A | + |
Hypothalamus | N/A | + | + | + |
Thalamus | N/A | N/A | N/A | + |
Hippocampus | N/A | + | + | + |
Septum | N/A | N/A | N/A | + |
Dentate gyrus | N/A | N/A | + | + |
Subiculum | N/A | N/A | + | + |
Median eminence | N/A | N/A | N/A | + |
Mammillary nucleus | N/A | + | + | + |
Zona incerta | N/A | N/A | + | N/A |
Pituitary | N/A | N/A | N/A | + |
Mesencephalon | N/A | + | + | + |
Periacqueductal gray | N/A | N/A | + | + |
Dorsal raphe | N/A | N/A | N/A | + |
Subfornical organ | N/A | N/A | N/A | + |
Gasser ganglion | N/A | N/A | + | + |
Cerebral cortex | N/A | + | + | + |
Rostral migratory stream | N/A | N/A | + | + |
Brainstem | + | + | + | + |
Nucleus tractus solitarius | + | N/A | N/A | + |
Dorsal motor nucleus vagus | N/A | N/A | + | N/A |
Lateral reticular nucleus | + | N/A | N/A | N/A |
Area postrema | N/A | N/A | N/A | + |
The nervous system | ||||
Spinal cord | N/A | + | + | + |
DRGs | N/A | + | + | + |
Sciatic nerve | N/A | + | + | + |
Myenteric plexus | N/A | + | + | + |
Neuronal cells | N/A | + | + | + |
Astrocytic cells | N/A | + | + | + |
Microglia cells | N/A | − | + | + |
Schwann cells | N/A | + | + | + |
The gastrointestinal system | ||||
Stomach | + | + | + | + |
Fundus | + | + | + | + |
Pylorus | + | + | + | + |
Duodenum | + | N/A | + | + |
Jejunum | + | N/A | + | + |
Ileum | + | + | + | + |
Ileum mucosa | + | N/A | + | + |
Ileum muscolaris | + | + | + | N/A |
Cecum | + | + | + | − |
Colon | + | + | + | + |
Colon muscle layer | N/A | + | N/A | + |
Rectum | + | + | + | − |
Submucosal neurons | N/A | N/A | + | N/A |
Enteric plexus (neurons and fibres) | N/A | N/A | + | N/A |
Interstitial nerve cells | + | N/A | + | N/A |
Epithelial cells (crypt base) | N/A | N/A | + | N/A |
Mucosa epithelial cells | + | + | + | + |
Proximal glands | N/A | + | N/A | + |
Interstitium | N/A | + | N/A | + |
Mesenchyma | + | N/A | + | N/A |
Immune cells | ||||
Hematopoietic stem cells | N/A | + | + | + |
Monocytes | − | + | + | + |
Neutrophils | N/A | + | + | + |
Dentritic cells | N/A | + | N/A | N/A |
Granulocytes | N/A | + | + | + |
Mecrophages | + | + | + | + |
Lymphocites | + | N/A | + | + |
Ovary | ||||
Granulosa | + | N/A | + | + |
Theca cells | + | N/A | + | + |
Capillary endothelial cells | N/A | N/A | N/A | N/A |
Corpus luteum | + | N/A | + | + |
Uterus | ||||
Grandular epithelium | + | + | + | + |
Endothelial cells | + | + | + | + |
Stromal muscle cells | + | + | + | + |
Smooth muscle cells | + | + | + | + |
Placenta | + | N/A | + | − |
Testis | ||||
Leyding cells | + | N/A | N/A | N/A |
Spermatocytes | N/A | + | N/A | N/A |
Interstitium endothelial cells | N/A | N/A | + | + |
Prostate | N/A | N/A | + | − |
Heart | ||||
Cardiovascular tissue | + | N/A | + | N/A |
Cardiac cells | + | N/A | + | N/A |
Kidneys | ||||
Epithelial tubules | + | N/A | + | N/A |
Endothelial cells | N/A | N/A | + | + |
Adrenal glands | ||||
Glomerulosa | + | + | + | + |
Fasciculate cells | + | + | + | N/A |
Endothelial cells | N/A | + | + | + |
Liver | ||||
Kupffer cells | N/A | + | + | + |
Pancreas | ||||
Pancreatic islet | + | N/A | N/A | N/A |
Stellate cells | + | N/A | N/A | N/A |
Vascular endothelial cells | N/A | N/A | + | + |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Amodeo, G.; Franchi, S.; Galimberti, G.; Riboldi, B.; Sacerdote, P. The Prokineticin System in Inflammatory Bowel Diseases: A Clinical and Preclinical Overview. Biomedicines 2023, 11, 2985. https://doi.org/10.3390/biomedicines11112985
Amodeo G, Franchi S, Galimberti G, Riboldi B, Sacerdote P. The Prokineticin System in Inflammatory Bowel Diseases: A Clinical and Preclinical Overview. Biomedicines. 2023; 11(11):2985. https://doi.org/10.3390/biomedicines11112985
Chicago/Turabian StyleAmodeo, Giada, Silvia Franchi, Giulia Galimberti, Benedetta Riboldi, and Paola Sacerdote. 2023. "The Prokineticin System in Inflammatory Bowel Diseases: A Clinical and Preclinical Overview" Biomedicines 11, no. 11: 2985. https://doi.org/10.3390/biomedicines11112985